Explanipedia

MON-129 Long term efficacy of BRAF and MEK Inhibitors without adjuvant radiotherapy in Residual Papillary Craniopharyngioma: A Case Report Open

Merav Serebro, Yona Greenman, Dror Limon · 2025

Disclosure: M. Serebro: None. Y. Greenman: None. D. Limon: None. Background: Craniopharyngiomas are rare intracranial tumors with an annual incidence of 0.16 per 100,000 individuals1. They are histologically categorized into adamantinomato…

Stereotactic Radiotherapy to the Prostate and Pelvic Lymph Nodes for High-Risk and Very High-Risk Prostate Cancer in a Setting with a Hydrogel Spacer: A Toxicity Report Open

Elisha Fredman, Roi Tschernichovsky, Danielle Shemesh, Miriam Weinstock-Sabbah, Ruth Dadush Azuz , et al. · 2025

Background/Objectives: Stereotactic radiotherapy (SABR) is a recognized standard treatment modality for localized prostate cancer, though data is limited regarding the risk of increased toxicity when including the elective nodes (ENI) for …

Stem the blood flow: beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients Open

Yosef Laviv, Ohad Regev, Andrew A. Kanner, Susana Fichman, Dror Limon , et al. · 2024

The role of a radiopaque peri-rectal hydrogel spacer in aiding accurate daily image-guidance for prostate stereotactic radiotherapy Open

Oded Icht, Shir Schlosser, Miriam Weinstock-Sabbah, Mor Rephael, Dimitri Bragilovski , et al. · 2024

Introduction Precise patient positioning with image guidance (IGRT) is essential for safe prostate radiotherapy. We present the first report of utilizing a CT-visible hydrogel spacer, used to decrease rectal radiation dose, as a surrogate …

SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer Open

Elisha Fredman, Oded Icht, Assaf Moore, Dimitri Bragilovski, Jonathan Kindler , et al. · 2024

Background Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiotherap…

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Open

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara , et al. · 2024

Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment Open

Itamar Averbuch, Roi Tschernichovsky, Shlomit Yust‐Katz, Ofer Rotem, Dror Limon , et al. · 2024

Introduction Historically, patients with brain metastasis (BM) have been excluded from clinical trials investigating treatments for non-small cell lung cancer (NSCLC) due to their unfavorable prognosis. Advanced treatments have increased s…

Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria Open

Sara Faye Borenstein, Ruth Eliahou, Alexandra Amiel, Alisa Talianski, Jonathan Ofer , et al. · 2024

Background Meningiomas are the most common primary tumor in the central nervous system. About 15%–20% are aggressive and tend to recur and progress despite conventional treatment. Bevacizumab has been found to be effective in the treatment…

A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor Open

Dror Limon, Alexandra Amiel, Shaked Even Haim, Noa Gordon, Roi Tschernichovsky , et al. · 2024

Background Atypical and anaplastic meningiomas account for 20% of all meningioma cases. Solitary fibrous tumor (SFT) is a type of soft tissue sarcoma with similar attributes to meningioma. For patients with refractory or recurrent disease …

Converging Survival Trends in Non-Small Cell Lung Cancer Patients With and Without Brain Metastasis Receiving State-of-the-Art Treatment Open

Itamar Averbuch, Roi Tschernichovsky, Shlomit Yust‐Katz, Ofer Rotem, Dror Limon , et al. · 2023

Introduction: Historically, patients with brain metastasis (BM) have been excluded from clinical trials investigating treatments for non-small cell lung cancer (NSCLC) due to their unfavorable prognosis. Advanced treatments have increased …

Pancreatic cancer outcome—local treatment with radiation using MRI-LINAC Open

Galit Almog, Raphael M. Pfeffer, Svetlana Zalmanov, Vladislav Grinberg, Y. Lipsky , et al. · 2023

Introduction Stereotactic MR-guided on-table adaptive radiotherapy (SMART) allows the precise delivery of high-dose radiation to tumors in great proximity to radiation-sensitive organs. The aim of this study is to evaluate the toxicity and…

NCMP-03. SHORT AND LONG TERM EFFICACY OF BEVACIZUMAB THERAPY FOR RADIATION NECROSIS IN BRAIN METASTASES Open

H. Nobel, Jonathan Ofer, Schlomit Yust-Kayz, Sara Borenstein, Tali Sigal , et al. · 2023

PURPOSE Brain radionecrosis (RN) is a frequent, and often life devastating complication of stereotactic radiotherapy (SRS) for brain metastases. There is no standard treatment for RN. Bevacizumab is often proposed although data regarding i…

NIMG-74. COMPARING VOLUMETRIC GROWTH-RATE AND RANO CRITERIA IN DETERMINING THE RESPONSE OF MENINGIOMA TO BEVACIZUMAB THERAPY Open

Sara Borenstein, Alexandra Amiel, Tali Siegal, Omer Gal, Dror Limon , et al. · 2023

Meningioma is the most prevalent primary tumor in the central nervous system (CNS). Although mostly benign, 15- 20% are aggressive and tend to recur and progress despite surgery and adjuvant radiation. Recent publications show that bevaciz…

EP09.04-03 Survival of Non-small Cell Lung Cancer with and without Brain Metastasis - Shifting to a Merging Survival Curves Era Open

I. Averbuch, Alona Zer, Roi Tschernichovsky, Shlomit Yust‐Katz, Ofer Rotem , et al. · 2023

KS03.5.A COMPARING VOLUMETRIC GROWTH-RATE AND RANO CRITERIA IN DETERMINING THE RESPONSE OF MENINGIOMA TO BEVACIZUMAB THERAPY Open

S Borenstein, Alexandra Amiel, T. Siegal, Omer Gal, Dror Limon , et al. · 2023

INTRODUCTION Meningioma is the most prevalent primary tumor in the central nervous system (CNS). Although mostly benign, 15- 20% are aggressive and tend to recur and progress despite surgery and adjuvant radiation. Recent publications show…

SABR-Dual: A phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer Open

Elisha Fredman, Oded Icht, Assaf Moore, Dimitri Bragilovski, Yoni Kindler , et al. · 2023

Background: Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiothera…

Same-day versus delayed simulation imaging after placement of a perirectal hydrogel spacer for prostate radiotherapy Open

Elisha Fredman, Miriam Weinstock-Sabbah, Oded Icht, Assaf Moore, Tzippora Shochet , et al. · 2023

Introduction Placement of a perirectal hydrogel spacer has been demonstrated to reduce the risk of rectal toxicity from prostate radiation. Practices vary regarding the timing of CT simulation after hydrogel placement, and the ideal schedu…

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) Open

Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem , et al. · 2022

Brain metastases in patients with ovarian cancer Open

Dror Limon, Eliya Shachar, Ido Wolf, Lyri Adar, Shira Peleg Hasson , et al. · 2022

Brain metastasis (BM) are uncommon among women with epithelial ovarian cancer (EOC). The frequency, risk factors and clinical repercussions of BM in these patients are not well described. We retrospectively evaluated EOC patients treated a…

Acute Lymphoblastic Leukemia Relapse Limited to the Anterior Chamber of the Eye and Treated with Novel CAR T-Cell Therapy Open

Nir Gomel, Eliya Levinger, Ron Ram, Dror Limon, Zohar Habot‐Wilner · 2021

Acute lymphoblastic leukemia (ALL) is a malignant neoplasm of the blood stem cells, characterized by increased formation of immature lymphocytes. Ocular manifestations may vary with ocular, adnexal, and orbital involvement. In this case re…

NIMG-05. DIFFERENCES IN VASCULARITY BETWEEN RECURRENT GLIOBLASTOMA AND BRAIN METASTASIS USING DYNAMIC CONTRAST ENHANCED MRI Open

Dafna Ben Bashat, Deborah T. Blumenthal, Dror Limon, Orna Aizenstein, Idan Bressler , et al. · 2021

In recent years, several automatic methods have been proposed to differentiate between brain tumor recurrence and treatment-related changes following radiotherapy, based on conventional and advanced MRI methods. Vascular parameters extract…

CTIM-31. A PHASE II, OPEN-LABEL, SINGLE ARM TRIAL OF PEMBROLIZUMAB FOR REFRACTORY ATYPICAL AND ANAPLASTIC MENINGIOMA AND HEMANGIOPERICYTOMA Open

Shlomit Yust‐Katz, Alexandra Amiel, Shlomit Yust‐Katz, Dror Limon · 2021

BACKGROUND Grade II and III meningiomas are invasive tumors which tend to recur following initial treatment and are associated with shorter survival (relative to grade I). Hemangiopericytoma (HPC) is a dural based tumor that originates in …

906 Characteristics of brain metastasis in ovarian cancer patients Open

Tamar Safra, Eduardo Shahar, Lyri Adar, S Peleg Hassom, A Harpaz , et al. · 2021

Introduction/Background* Brain metastasis (BM) are uncommon among ovarian cancer (OC) patients. Their frequency, risk factors and clinical repercussions are not well described. We assessed OC patients who developed BM, the role of BRCA sta…

1206P UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN) Open

Jair Bar, Waleed Kian, M. Wolner, Sofie Derijcke, Nicolas Girard , et al. · 2021

OTHR-03. Brain Metastasis Among Ovarian Cancer Patients Open

Dror Limon, Eliya Shachar, Lyri Adar, Shira Peleg Hasson, Tamar Safra · 2021

Background Brain metastasis (BM) are uncommon among ovarian cancer (OC) patients. Their frequency, risk factors and clinical repercussions are not well described. We assessed OC patients who developed BM, the role of BRCA status and surviv…

RTID-12. PHASE 2 TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) PLUS RADIATION THERAPY (RT) PLUS TEMOZOLAMIDE (TMZ) COMPARED TO RT PLUS TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM) Open

Rachel Grossman, Dror Limon, Felix Bokstein, Carmit Ben Harosh, Deborah T. Blumenthal , et al. · 2020

OBJECTIVE In the EF-14 phase 3 trial, TTFields 9200 kHz) added to maintenance TMZ increased median OS to 20.9 months versus 16.0 months with maintenance TMZ (p< 0.001) in ndGBM. Preclinical investigations showed that TTFields/RT have a …

Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study Open

Felix Bokstein, Deborah T. Blumenthal, Dror Limon, Carmit Ben Harosh, Zvi Ram , et al. · 2020

Background: TTFields are a loco-regional, anti-mitotic treatment comprising low-intensity alternating electric fields. In the EF-14 study of newly diagnosed glioblastoma (ndGBM), TTFields in combination with temozolomide (TMZ) signi…

ACTR-46. TUMOR TREATING FIELDS COMBINED WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA: FINAL RESULTS FROM A PILOT STUDY Open

Rachel Grossman, Dror Limon, Felix Bokstein, Deborah T. Blumenthal, Camit Ben Harush , et al. · 2019

BACKGROUND Tumor Treating Fields (TTFields) are a non-invasive, loco-regional, anti-mitotic treatment comprising low intensity alternating electric fields approved for GBM. Preclinical data show that TTFields have a radio-sensitizing effec…

Treatment Response Assessment Maps (TRAMs): Increased/Decreased Sensitivity to Tumor As a Function of Acquisition/Analysis Parameters Open

Yael Mardor, David Last, Dianne Daniels, Arielle Tylim, Dvora Nass , et al. · 2019

P14.79 Randomized phase II trial of Tumor Treating Fields plus radiation therapy plus temozolomide compared to radiation therapy plus temozolomide in patients with newly diagnosed glioblastoma Open

Dror Limon, Felix Bokstein, Deborah T. Blumenthal, Carmit Ben Harush, Zvi Ram , et al. · 2019

BACKGROUND In last decade, there were numerous attempts to improve the outcome of patients with glioblastoma (GBM), but even after maximal surgical resection, radiation therapy (RT) and temozolomide (TMZ), followed by maintenance TMZ for 6…

Dror Limon YOU? Author Swipe